Amelia Jones | 15/12/2025
This poster was presented at ISPOR 2025 in Glasgow (9-12 November).
Author Cameron Lilley explains the motivation behind the research and provides further insight into the findings.
Loading Viewer...
The ISPOR ‘Value Flower,’ introduced in 2018, challenged traditional health technology assessment (HTA) frameworks by spotlighting value elements often overlooked in conventional models. While QALYs remain central, the Value Flower identifies 12 elements – such as hope and convenience – that reflect broader patient and societal benefits. Despite growing interest, their formal role in UK HTA decision-making has remained unclear. Our research set out to examine how NICE considers these “uncaptured benefits” and whether they influence recommendation decisions.
This study fills a critical gap: no previous analysis has explored the extent to which NICE incorporates broader value elements beyond the reference case.
Our findings reveal an important trend. References to benefits beyond QALYs have increased since 2018, with the most common uncaptured benefits including impacts on healthcare delivery, convenience, lifestyle improvements, and changes to disease progression. Notably, Committee B referenced these elements most often, suggesting variability across appraisal committees.
For manufacturers, understanding which value elements NICE acknowledges most frequently can inform submission strategies. For NICE, the findings underscore the need for greater transparency and consistency. Expanding the reference case and aligning theoretical frameworks with practical methodologies would ensure broader value elements are applied systematically.
As healthcare decision-making evolves, incorporating uncaptured benefits will be essential to reflect the true value of innovation and deliver fair, informed recommendations.
If you have any questions or would like to hear more about our research please contact Cameron Lilley, Principal HTA Consultant at HEOR: cameron.lilley@heor.co.uk.